Joseph Bolen, who quietly left high-profile biotech Moderna Therapeutics earlier this year, has joined startup factory PureTech Health to help the group ferret out promising technologies and launch new companies.
Moderna Therapeutics is launching the third new personalized cancer vaccine venture in as many weeks, spinning out its messenger RNA tech into a separate entity dubbed Caperna.
Moderna Therapeutics' top scientist has quietly left the much-discussed company after two years at the helm of its R&D operation, walking away from a cash-flush biotech with big ambitions.
Promising preclinical work on messenger RNA therapies has provided Moderna Therapeutics with the number one spot on CNBC's list of the most disruptive new technologies now in the spotlight.
Shuffling a thick deck of preclinical programs, Moderna Therapeutics has dealt out a fresh biotech hand for the third in its series of venture units tasked with recruiting a new team to shepherd messenger RNA programs into the clinic.
While a long list of biopharma companies have been dropping the ax on R&D staffers in recent weeks and months, some of the top execs being shown the exit are finding that new doors are opening as fast as old positions are whisked away. Today, Tal Zaks underscored the bright side of restructuring, being named chief medical officer at Moderna Therapeutics a month after he was among 100 oncology R&D staffers who were ushered out at Sanofi in a recent reorganization.
With a big assist from Moderna's recent monster round, the biotech industry came within a rounding error of breaking the record for new venture investing in 2014, racking up $5.96 billion in total investments in a frenzied year of deals, data and buyouts, according to The MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based on data from Thomson Reuters.
Pharma giant Merck is buying into the allure of Moderna Therapeutics and its radical promise to transform patients' cells into drug factories, committing $100 million and joining a host of collaborators and investors betting the early-stage biotech is sitting on transformational technology.
Superlatively well-funded biotech Moderna Therapeutics has raised another $450 million in venture cash, planning to staff up and buckle down on a slew of preclinical candidates that promises to transform patients' cells into drug factories.
Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology.